Be sure to check our sister interview main ratings news website

N4 Pharma Make considerable progress on Nuvec, well positioned for collaborations (Interview)

N4 Pharma Plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss results for the year ended 31 December 2020. Nigel talks us through the highlights of the year, updates us on the new refined strategy to focus on three work streams, explains what the Patent in relation to Nuvec means for the company and lets us know what investors can expect from N4 Pharma in the near future.

N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for cancer and vaccine treatments using its unique silica nanoparticle delivery system called Nuvec®.

The business model is to partner with companies developing novel antigens for cancer and vaccine treatments to use Nuvec® as the delivery vehicle to get their antigen into cells to express the protein needed for the required immunity. As these products progress through pre clinical and clinical programs, the company will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    N4 Pharma

    More articles like this

    N4 Pharma

    N4 Pharma acceleration in understanding of the capabilities of Nuvec

    20th September 2021

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, has announced its unaudited interim results for the six months ended 30 June 2021. Highlights: ·      Continued strategy to

    N4 Pharma

    N4 Pharma Q&A: Good, strong, steady progress (LON:N4P)

    27th May 2021

    N4 Pharma’s Nigel Theobald discusses the Material Transfer Agreements, collaborating with more partners, the in vivo studies, how the work done under the MTA may negate the need for the Company to do its own proof of concept work and what investors can expect in the coming months in this exclusive interview with DirectorsTalk.

    N4 Pharma

    N4 Pharma Nuvec showing fantastic results (Interview)

    24th May 2021

    N4 Pharma plc (LON:N4P) CEO Nigel Theobald joins DirectorsTalk to discuss its operations update. Nigel explains what is involved in the Material Transfer Agreements that have been announced, whether these are exclusive, how the work done

    N4 Pharma

    N4 Pharma Q&A: A pivotal time for the company (LON:N4P)

    26th February 2021

    N4 Pharma’s Nigel Theobald discusses final results, updates on the three work streams, the European patent for Nuvec & what this means for the company and what investors can expect in the near future in this exclusive interview with DirectorsTalk.

    N4 Pharma

    N4 Pharma AGM to be held at 10.00am on 24 March 2021

    25th February 2021

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that the Company’s audited accounts for the year ended 31 December 2020, together with the

    DirectorsTalk

    N4 Pharma raises £2 million through placing

    9th December 2020

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has announced that it has raised £2 million (before expenses) through a placing of 25,000,000 new ordinary

    DirectorsTalk

    N4 Pharma update on Nanomerics research collaboration

    3rd December 2020

    N4 Pharma Plc (LON:N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, has provided the following update on its ongoing research collaboration agreement with Nanomerics Limited. As announced on

    DirectorsTalk

    N4 Pharma Q&A: Confirming Nuvec’s versatility (LON:N4P)

    12th November 2020

    N4 Pharma’s Nigel Theobald discusses their latest operational update, the importance of demonstrating formulation, key milestones for the COVID-19 proof of concept programme, whyan orally administered vaccine has greater challenges than a subcutaneous injection and what news flow investors can expect from the company for the rest of the year in this exclusive interview with DirectorsTalk.

    © 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.